FATE
Fate Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+15/100
Last price
2.30
▼ 0.13 (5.35%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.43
Prev close
2.43
Day high
2.49
Day low
2.29
Volume
1.14M
Market cap
$274.39M
P/E (TTM)
—
52W range
0.95 – 3.23
Day trading desk
Gap from prior close
-0.00%
Prior close 2.43
VWAP
2.32
-0.85% from price
Relative volume
1.11×
Normal
Session range
8.97%
2.29 – 2.49
Position in range
7%
Near session low
ATR (14D)
0.16
6.99% of price
Prior day high
2.58
PDH
Prior day low
2.29
PDL
Bid / ask spread
—
Quote not published
Session volume
2.14M
Avg 1.92M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.78%
-5.7%
1M
-7.66%
-8.8%
3M
-21.84%
-26.4%
6M
+99.13%
+80.9%
YTD
+133.67%
+119.4%
1Y
+89.26%
+72.8%
3Y
+8.02%
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FATE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+79.38K
Net buying
Buy transactions
3
216.66K shares
Sell transactions
4
137.28K shares
Net transactions
+7
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
1.28M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 4, 26 | TAHL CINDY R Officer |
SELL | 38.80K | $95.41K | Direct |
| Aug 4, 26 | VALAMEHR BAHRAM Chief Executive Officer |
SELL | 43.95K | $108.10K | Direct |
| May 20, 26 | TAHL CINDY R Officer |
SELL | 25.59K | $48.08K | Direct |
| May 20, 26 | VALAMEHR BAHRAM Chief Executive Officer |
SELL | 28.95K | $54.48K | Direct |
| May 6, 26 | TAHL CINDY R Officer |
CONVERSION | 166.66K | $208.00K | Direct |
| May 5, 26 | RASTETTER WILLIAM H Director |
CONVERSION | 25.00K | $42.25K | Direct |
| May 5, 26 | EPSTEIN ROBERT S Director |
CONVERSION | 25.00K | $42.25K | Direct |
| Jan 15, 26 | TAHL CINDY R Officer |
STOCK | 100.00K | $0 | Direct |
| Jan 15, 26 | VALAMEHR BAHRAM Chief Executive Officer |
STOCK | 335.00K | $0 | Direct |
| Jan 15, 26 | ADAWI KAMAL Chief Financial Officer |
STOCK | 25.00K | $0 | Direct |
| Jan 9, 26 | TAHL CINDY R Officer |
SELL | 10.59K | $11.28K | Direct |
| Jan 9, 26 | VALAMEHR BAHRAM Chief Executive Officer |
SELL | 5.19K | $5.56K | Direct |
| Oct 20, 25 | ADAWI KAMAL Chief Financial Officer |
STOCK | 75.00K | $0 | Direct |
| Aug 4, 25 | TAHL CINDY R Officer |
SELL | 9.04K | $9.57K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAWI KAMAL |
Chief Financial Officer | 100.00K | Stock Award(Grant) |
BRESSI JEROME CHARLES |
Officer | 335.20K | Stock Award(Grant) |
EPSTEIN ROBERT S |
Director | 36.33K | Conversion of Exercise of derivative security |
RASTETTER WILLIAM H |
Director | 642.42K | Conversion of Exercise of derivative security |
REDMILE GROUP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
TAHL CINDY R |
Officer | 589.36K | Sale |
VALAMEHR BAHRAM |
Chief Executive Officer | 591.82K | Sale |
Fundamentals
Market cap$274.39M
Enterprise value$196.30M
Revenue (TTM)$6.49M
Gross profit$-77.93M
EBITDA$-120.50M
Net income$-126.00M
EPS (TTM)$-0.99
Free cash flow$-48.66M
Total cash$153.77M
Total debt$75.67M
Book value / share$1.32
Shares outstanding119.82M
Float105.48M
Short % of float8.85%
Dividend yield0.00%
Beta (5Y)2.53
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.37
PEG ratio—
Price / sales—
Price / book1.74
EV / revenue30.24
EV / EBITDA-1.63
Gross margin0.00%
Operating margin-1495.39%
Profit margin0.00%
Return on equity-60.75%
Return on assets-26.22%
Debt / equity49.32
Current ratio4.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.65M | $13.63M | $63.53M | $96.30M | -51.2% |
| Operating revenue | $6.65M | $13.63M | $63.53M | $96.30M | -51.2% |
| Research & development | $107.83M | $135.00M | $172.60M | $320.45M | -20.1% |
| Selling, general & admin | $46.52M | $74.17M | $81.45M | $84.23M | -37.3% |
| Total operating expense | $154.35M | $209.17M | $254.04M | $404.69M | -26.2% |
| Operating income | -$147.70M | -$195.54M | -$190.51M | -$308.39M | +24.5% |
| Net interest income | $11.05M | $17.29M | $17.19M | $5.84M | -36.1% |
| Pre-tax income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | +26.8% |
| Net income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | +26.8% |
| Net income to common | -$136.31M | -$186.26M | -$160.93M | -$281.72M | +26.8% |
| Basic EPS | -1.15 | -1.64 | -1.64 | -2.91 | +29.9% |
| Diluted EPS | -1.15 | -1.64 | -1.64 | -2.91 | +29.9% |
| EBIT | -$147.70M | -$195.54M | -$190.51M | -$308.39M | +24.5% |
| EBITDA | -$134.80M | -$176.58M | -$172.23M | -$294.63M | +23.7% |
| Basic shares | 118.79M | 113.69M | 98.41M | 96.83M | +4.5% |
| Diluted shares | 118.79M | 113.69M | 98.41M | 96.83M | +4.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $46.63M | $36.06M | $41.87M | $61.33M | +29.3% |
| Cash & short-term investments | $203.66M | $279.07M | $315.18M | $436.23M | -27.0% |
| Accounts receivable | $916.00K | $3.54M | $1.83M | $38.48M | -74.1% |
| Total current assets | $208.70M | $291.91M | $331.54M | $502.07M | -28.5% |
| Property, plant & equipment | $98.53M | $110.89M | $158.51M | $176.09M | -11.1% |
| Total assets | $318.94M | $440.69M | $506.22M | $705.56M | -27.6% |
| Total current liabilities | $36.07M | $38.52M | $39.09M | $114.05M | -6.4% |
| Total debt | $77.85M | $85.27M | $103.54M | $109.34M | -8.7% |
| Total liabilities | $111.75M | $121.97M | $137.80M | $221.62M | -8.4% |
| Retained earnings | -$1.53B | -$1.40B | -$1.21B | -$1.05B | -9.8% |
| Shareholder equity | $207.18M | $318.73M | $368.42M | $483.94M | -35.0% |
| Working capital | $172.63M | $253.39M | $292.45M | $388.02M | -31.9% |
| Net tangible assets | $207.18M | $318.73M | $368.42M | $483.94M | -35.0% |
| Shares issued | 115.36M | 113.93M | 98.63M | 97.29M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | +26.8% |
| Depreciation & amortisation | $12.90M | $18.96M | $18.28M | $13.76M | -32.0% |
| Stock-based compensation | $24.92M | $41.50M | $43.46M | $78.73M | -39.9% |
| Change in working capital | -$3.74M | -$1.96M | $19.18M | -$34.71M | -91.1% |
| Operating cash flow | -$106.08M | -$122.87M | -$132.26M | -$248.21M | +13.7% |
| Capital expenditure | -$5.95M | -$730.00K | -$6.15M | -$35.57M | -715.5% |
| Investing cash flow | $111.17M | $12.22M | $112.67M | $166.75M | +809.9% |
| Financing cash flow | $5.49M | $99.89M | $85.00K | $9.21M | -94.5% |
| Free cash flow | -$112.04M | -$123.60M | -$138.42M | -$283.77M | +9.4% |
| End cash position | $56.85M | $46.28M | $57.05M | $76.56M | +22.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.08M | $1.30M | $1.37M | $1.74M | $1.91M | +60.3% |
| Operating revenue | $2.08M | $1.30M | $1.37M | $1.74M | $1.91M | +60.3% |
| Research & development | $24.39M | $24.70M | $25.43M | $25.84M | $27.43M | -1.3% |
| Selling, general & admin | $8.83M | $9.60M | $10.66M | $10.64M | $11.45M | -8.0% |
| Total operating expense | $33.22M | $34.30M | $36.09M | $36.48M | $38.88M | -3.2% |
| Operating income | -$31.13M | -$33.00M | -$34.72M | -$34.73M | -$36.97M | +5.7% |
| Net interest income | $1.55M | $1.87M | $2.22M | $2.58M | $2.92M | -16.7% |
| Pre-tax income | -$30.16M | -$31.21M | -$32.37M | -$32.25M | -$34.07M | +3.4% |
| Net income | -$30.16M | -$31.21M | -$32.37M | -$32.25M | -$34.07M | +3.4% |
| Net income to common | -$30.16M | -$31.21M | -$32.37M | -$32.25M | -$34.07M | +3.4% |
| Basic EPS | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | +3.8% |
| Diluted EPS | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | +3.8% |
| EBIT | -$31.13M | -$33.00M | -$34.72M | -$34.73M | -$36.97M | +5.7% |
| EBITDA | -$28.35M | -$30.08M | -$31.66M | -$31.51M | -$33.69M | +5.7% |
| Basic shares | 120.40M | 120.03M | 119.25M | 119.00M | 118.53M | +0.3% |
| Diluted shares | 120.40M | 120.03M | 119.25M | 119.00M | 118.53M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.43M | $39.57M | $46.63M | $40.62M | $41.25M | -18.0% |
| Cash & short-term investments | $153.77M | $174.82M | $203.66M | $215.42M | $222.83M | -12.0% |
| Accounts receivable | $703.00K | $704.00K | $916.00K | $682.00K | $1.40M | -0.1% |
| Total current assets | $157.95M | $179.53M | $208.70M | $221.25M | $230.40M | -12.0% |
| Property, plant & equipment | $92.10M | $95.34M | $98.53M | $101.89M | $104.91M | -3.4% |
| Total assets | $260.10M | $284.92M | $318.94M | $343.67M | $371.63M | -8.7% |
| Total current liabilities | $32.59M | $30.69M | $36.07M | $28.11M | $28.67M | +6.2% |
| Total debt | $75.67M | $76.78M | $77.85M | $79.25M | $81.33M | -1.4% |
| Total liabilities | $106.67M | $105.21M | $111.75M | $109.61M | $110.27M | +1.4% |
| Retained earnings | -$1.60B | -$1.57B | -$1.53B | -$1.50B | -$1.47B | -1.9% |
| Shareholder equity | $153.44M | $179.71M | $207.18M | $234.07M | $261.36M | -14.6% |
| Working capital | $125.36M | $148.84M | $172.63M | $193.14M | $201.72M | -15.8% |
| Net tangible assets | $153.44M | $179.71M | $207.18M | $234.07M | $261.36M | -14.6% |
| Shares issued | 116.69M | 116.27M | 115.36M | 115.34M | 114.66M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$30.16M | -$31.21M | -$32.37M | -$32.25M | -$34.07M | — | +3.4% |
| Depreciation & amortisation | $2.78M | $2.92M | $3.06M | $3.23M | $3.28M | — | -4.7% |
| Stock-based compensation | $3.52M | $3.93M | $5.53M | $4.86M | $7.15M | — | -10.5% |
| Change in working capital | $1.19M | -$5.96M | $1.05M | $504.00K | $73.00K | — | +120.0% |
| Operating cash flow | -$23.43M | -$30.82M | -$23.31M | -$24.37M | -$24.59M | — | +24.0% |
| Capital expenditure | -$80.00K | -$239.00K | -$1.19M | -$2.20M | -$1.36M | — | +66.5% |
| Investing cash flow | $14.56M | $23.59M | $27.63M | $21.27M | $19.59M | — | -38.3% |
| Financing cash flow | — | — | $1.69M | $2.48M | $1.32M | $0 | — |
| Free cash flow | -$23.51M | -$31.06M | -$24.51M | -$26.58M | -$25.95M | — | +24.3% |
| End cash position | $42.48M | $49.62M | $56.85M | $50.85M | $51.48M | — | -14.4% |
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
0.09
Positioning, not flow
Max pain
1.50
-34.5% from spot
ATM implied vol
276.6%
Nearest strike to spot
Skew (10% OTM)
+304.7%
Puts bid over calls
Call volume
78
Contracts, this expiry
Put volume
13
Contracts, this expiry
Heaviest call OI
2.00
177 contracts
Heaviest put OI
3.00
11 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.26 | -0.25 | +2.6% |
| Mar 2026 | -0.28 | -0.26 | +5.5% |
| Dec 2025 | -0.27 | -0.27 | +0.5% |
| Sep 2025 | -0.28 | -0.27 | +4.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.26 | 8 | $1.20M | -31.0% |
| Next quarter | -0.27 | 8 | $1.20M | -12.2% |
| Current year | -1.02 | 8 | $5.65M | -15.0% |
| Next year | -0.97 | 8 | $4.77M | -15.6% |
Analyst targets & ownership
Mean target$5.74
High target$8.00
Low target$2.20
Implied upside149.76%
Analyst count9
ConsensusBUY
Strong buy / Buy1 / 4
Hold6
Sell / Strong sell0 / 0
Held by insiders1.07%
Held by institutions69.04%
Institutions holding196
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.36
-2.46% from price
SMA 20
2.40
-4.48% from price
SMA 50
2.47
-7.41% from price
SMA 100
2.43
-5.41% from price
SMA 200
1.86
+22.81% from price
EMA 12
2.37
-3.12% from price
EMA 26
2.41
-4.68% from price
EMA 50
2.43
-5.40% from price
RSI (14)
42.2
Neutral
MACD (12,26,9)
-0.04
Hist -0.01
ATR (14)
0.16
7.02% of price
Realised vol 30D
44.4%
Annualised
Bollinger upper
2.57
20, 2σ
Bollinger lower
2.23
20, 2σ
50 / 200 cross
Golden
2.47 vs 1.86
Trend bias
Above 200
+22.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.76
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
44.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.8%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
0.16
7.02% of price
Beta (reported)
2.53
5Y monthly, from filing
Short interest
Shares short
9.39M
Prior 8.51M
Change vs prior
+10.3%
Shorts adding
% of float
8.85%
Normal
% of shares out
7.83%
Against total outstanding
Days to cover
7.8
Crowded exit
Float
105.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 14, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 14, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 31, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Oct 27, 25 | Wedbush | UPGRADE | Neutral | Outperform |
| Oct 27, 25 | Needham | MAINTAINED | Hold | Hold |
| Aug 13, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jun 12, 25 | Needham | MAINTAINED | Hold | Hold |
| May 14, 25 | Barclays | MAINTAINED | Overweight | Overweight |
| May 14, 25 | Baird | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-06-04
Periodic Financial Reports
10-Q · 2026-05-13
Annual Report to Shareholders
ARS · 2026-04-24
Corporate Changes & Voting Matters
8-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2025-11-13
Headlines
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
GlobeNewswire · 6d ago
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires · 12d ago
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial
MT Newswires · 12d ago
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
GlobeNewswire · 12d ago
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
GlobeNewswire · 21d ago
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
GlobeNewswire · 28d ago
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
GlobeNewswire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.